A Glimpse Into The Expert Outlook On Halozyme Therapeutics Through 8 Analysts
Portfolio Pulse from Benzinga Insights
8 analysts have shared their evaluations of Halozyme Therapeutics (NASDAQ:HALO) over the past three months, showing a mix of bullish and somewhat bullish perspectives. The average 12-month price target has decreased by 8.22% to $52.62. Key financial metrics indicate strong profitability and revenue growth, but the company faces challenges with high debt levels.
June 04, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Analysts have mixed sentiments on Halozyme Therapeutics with a decreased average price target of $52.62. The company shows strong profitability and revenue growth but faces challenges with high debt levels.
The mixed analyst ratings and decreased price target suggest a neutral short-term impact on the stock price. While the company shows strong financial performance, high debt levels could be a concern for investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100